Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01885689 · OUTCOME

Progression-free Survival at 2 Years

Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia · Source last updated 2026-08-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percent probability
Interval / dispersion
95% Confidence Interval
Time frame
From start of protocol treatment to death due to any cause, disease relapse/progression, or last follow-up, whichever comes first, assessed up to 2 years.

What was measured

Progression-free survival (PFS) is defined as time from start of protocol treatment to disease relapse/progression, death or last contact, whichever occurs first. Progression-free survival was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula.

Groups in this outcome

Treatment (Clofarabine, Melphalan, Transplant)

CONDITIONING REGIMEN: Patients receive clofarabine IV over 2 hours on days -9 to -5 and melphalan IV over 30 minutes on day -4. TRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0. GVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or PO and sirolimus PO once daily with taper per City of Hope standard operating procedure. clofarabine: Given IV melphalan: Given IV allogeneic hematopoietic stem cell transplantation: Undergo allogeneic hematopoietic stem cell transplant tacrolimus: Given IV or PO sirolimus: Given PO Pharmacological Study: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Clofarabine, Melphalan, Transplant)52

Reported measurements

Source class 1
Values in percent probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Clofarabine, Melphalan, Transplant)54Not reported3966Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        39
        upper Limit
        66
        value
        54
denoms
  1. counts
    1. group Id
      OG000
      value
      52
    units
    Participants
description
Progression-free survival (PFS) is defined as time from start of protocol treatment to disease relapse/progression, death or last contact, whichever occurs first. Progression-free survival was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula.
dispersion Type
95% Confidence Interval
groups
  1. description
    CONDITIONING REGIMEN: Patients receive clofarabine IV over 2 hours on days -9 to -5 and melphalan IV over 30 minutes on day -4. TRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0. GVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or PO and sirolimus PO once daily with taper per City of Hope standard operating procedure. clofarabine: Given IV melphalan: Given IV allogeneic hematopoietic stem cell transplantation: Undergo allogeneic hematopoietic stem cell transplant tacrolimus: Given IV or PO sirolimus: Given PO Pharmacological Study: Correlative studies
    id
    OG000
    title
    Treatment (Clofarabine, Melphalan, Transplant)
param Type
NUMBER
reporting Status
POSTED
time Frame
From start of protocol treatment to death due to any cause, disease relapse/progression, or last follow-up, whichever comes first, assessed up to 2 years.
title
Progression-free Survival at 2 Years
type
PRIMARY
unit Of Measure
percent probability

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice